Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bayesian Adaptive Phase II Randomized Trial Comparing Ivonescimab, Ivonescimab Plus Nimotuzumab, Liposomal Mitoxantrone Plus Anti-PD-1 Antibody, and Liposomal Irinotecan Plus S-1 in Patients With PD-1-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT07070479 is registered in ClinicalTrials.gov with Ming-Yuan Chen as lead sponsor.

NCT NCT07070479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07070479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bayesian Adaptive Phase II Randomized Trial Comparing Ivonescimab, Ivonescimab Plus Nimotuzumab, Liposomal Mitoxantrone Plus Anti-PD-1 Antibody, and Liposomal Irinotecan Plus S-1 in Patients With PD-1-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
Lead sponsor
Ming-Yuan Chen
Phase
Phase 2
Overall status
Recruiting
Start date
June 24, 2025
Completion date
January 30, 2028
Enrollment
208 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic nasopharyngeal carcinoma